ebselen has been researched along with ritonavir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, SA; Banerjee, S; Gayen, S; Ghosh, K; Jha, T | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Darmawan, KK; Hung, A; Karagiannis, C; Karagiannis, TC; Liang, J; Ng, K; Pitsillou, E | 1 |
1 review(s) available for ebselen and ritonavir
| Article | Year |
|---|---|
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Topics: Antiviral Agents; Catalytic Domain; Coronavirus 3C Proteases; Cysteine Proteinase Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Molecular Docking Simulation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; SARS-CoV-2 | 2021 |
2 other study(ies) available for ebselen and ritonavir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
Topics: Amides; Antiviral Agents; Azoles; Coronavirus 3C Proteases; Coronavirus Protease Inhibitors; Humans; Isoindoles; Ligands; Lopinavir; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Organoselenium Compounds; Protein Multimerization; Ritonavir; SARS-CoV-2; Small Molecule Libraries | 2020 |